Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus Strong support for potential of XF-73 nasal product as alternative to mupirocin Brighton, United Kingdom – 18 October 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life […]